Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?

PURPOSE To evaluate the outcome, tolerance, and toxicity of stereotactic body radiotherapy, using image-guided robotic radiation delivery, for the treatment of patients with unresectable liver metastases. METHODS AND MATERIAL Patients were treated with real-time respiratory tracking between July 2007 and April 2009. Their records were retrospectively reviewed. Metastases from colorectal carcinoma and other primaries were not necessarily confined to liver. Toxicity was evaluated using National Cancer Institute Common Criteria for Adverse Events version 3.0. RESULTS Forty-two patients with 62 metastases were treated with two dose levels of 40 Gy in four Dose per Fraction (23) and 45 Gy in three Dose per Fraction (13). Median follow-up was 14.3 months (range, 3-23 months). Actuarial local control for 1 and 2 years was 90% and 86%, respectively. At last follow-up, 41 (66%) complete responses and eight (13%) partial responses were observed. Five lesions were stable. Nine lesions (13%) were locally progressed. Overall survival was 94% at 1 year and 48% at 2 years. The most common toxicity was Grade 1 or 2 nausea. One patient experienced Grade 3 epidermitis. The dose level did not significantly contribute to the outcome, toxicity, or survival. CONCLUSION Image-guided robotic stereotactic body radiation therapy is feasible, safe, and effective, with encouraging local control. It provides a strong alternative for patients who cannot undergo surgery.

[1]  M. Schell,et al.  A prospective pilot study of curative‐intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions , 2008, Cancer.

[2]  S. Kosuda,et al.  Feasibility of Frameless Stereotactic High-Dose Radiation Therapy for Primary or Metastatic Liver Cancer , 1998 .

[3]  F. Lohr,et al.  Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Schell,et al.  Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. , 2007, International journal of radiation oncology, biology, physics.

[5]  I. Lax,et al.  Radiosurgery for Tumors in the Body: Clinical Experience Using a New Method , 1998 .

[6]  D. Nagorney,et al.  Hepatic resection for noncolorectal, nonneuroendocrine metastases , 2005, Journal of Gastrointestinal Surgery.

[7]  M. Hoogeman,et al.  Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files. , 2009, International journal of radiation oncology, biology, physics.

[8]  Michael Flentje,et al.  Stereotactic Radiotherapy of Targets in the Lung and Liver , 2001, Strahlentherapie und Onkologie.

[9]  G. Lockwood,et al.  Phase I study of individualized stereotactic body radiotherapy of liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Ercolani,et al.  The Role of Liver Resections for Noncolorectal, Nonneuroendocrine Metastases: Experience With 142 Observed Cases , 2005, Annals of Surgical Oncology.

[11]  A. Siriwardena,et al.  Radiofrequency ablation of liver tumours: systematic review. , 2004, The Lancet Oncology.

[12]  Peter C Levendag,et al.  Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study , 2006, Acta oncologica.

[13]  U. Haedinger,et al.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases , 2006, Acta oncologica.

[14]  Robert D Timmerman,et al.  A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. , 2005, International journal of radiation oncology, biology, physics.

[15]  Y. Takai,et al.  Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. , 2004, International journal of radiation oncology, biology, physics.

[16]  Charles R. Thomas,et al.  Stereotactic Body Radiation Therapy: An Ablative Treatment Option for Primary and Secondary Liver Tumors , 2004, Annals of Surgical Oncology.

[17]  Richard Stang,et al.  Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.

[18]  P. Francescon,et al.  Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. , 2009, Anticancer research.

[19]  Frcsc Paul D. Greig MD,et al.  Survival After Hepatic Resection for Colorectal Metastases: A 10-Year Experience , 2006, Annals of Surgical Oncology.

[20]  A. Gardini,et al.  Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. , 2002, Archives of surgery.

[21]  L. Gaspar,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Petersen,et al.  Phase II study on stereotactic body radiotherapy of colorectal metastases , 2006, Acta oncologica.

[23]  S. Gallinger,et al.  Hepatic resection of noncolorectal nonneuroendocrine metastases , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  W. Franklin,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. van Kaick,et al.  Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. , 2003, International journal of radiation oncology, biology, physics.